AI 기반 망막 스크리닝 기기 시장 : 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the AI-driven retinal screening device market size is expected to grow from USD 484.53 million in 2025 to USD 570.52 million in 2026 and is forecast to reach USD 1,298.60 million by 2031 at 17.85% CAGR over 2026-2031.

This report is Segmented by Component (Hardware, Software, Services), Technology (Fundus Image-Based AI, OCT-Based AI, and More), Deployment (Cloud-Based, On-Premise), Application (Diabetic Retinopathy, AMD, and More), End User (Hospitals, Ophthalmology Clinics, and More), Geography (North America, Europe, and More), Market Forecasts are Provided in Terms of Value (USD).

Global AI-Driven Retinal Screening Device Market Trends and Insights

Rising Diabetes Burden and Undiagnosed Retinopathy Risk

The AI-driven retinal screening device market is being supported by a large and persistent pool of people who need regular eye screening but are still outside formal care pathways. In 2024, 589 million adults worldwide lived with diabetes, and 42.80% of them were undiagnosed, which left a very large population exposed to delayed retinal disease detection. A 2025 review covering 21 countries reported pooled diabetic retinopathy prevalence of 28.40% among people with diabetes, which supports the view that the screening burden is structurally large and long-lasting. Because 81% of people with diabetes live in low- and middle-income countries, the AI-driven retinal screening device market is not tightly tied to premium device affordability and is instead pushed by the need for scale and lower cost delivery. This pattern supports software-led platforms and portable screening workflows, since they can reach primary care sites and underserved populations faster than specialist-centered service models.

Shortage of Ophthalmologists and Specialist Bottlenecks

The AI-driven retinal screening device market is also advancing because the eye care workforce remains too limited and too unevenly distributed to support specialist-led screening at the needed scale. A 2026 workforce estimate placed the global supply at 275,551 ophthalmologists, or 34 per million people, with only 6 countries accounting for half of the total supply. India was reported to have only 1 ophthalmologist for every 65,000 people, which shows why demand is moving toward triage and screening models that do not depend on large specialist teams. The same supply gap appears in other regions, and published research has shown that even high-income countries face large future workforce requirements to maintain access standards. This makes AI screening less of an optional tool and more of a capacity substitute that helps referral networks absorb rising diabetes-related eye disease volumes.

Data Privacy, Model Governance, and Cross-Border Data Restrictions

The AI-driven retinal screening device market faces a meaningful restraint from tightening data governance rules across major healthcare systems. The European Health Data Space Regulation, published in March 2025, added new secondary-use governance obligations that interact with existing GDPR standards and complicate cross-border handling of health imaging data. China also introduced YY/T 1949-2024, its first industry-specific dataset standard for diabetic retinopathy fundus images, which signaled a more formal approach to training data quality and validation. German guidance issued in 2025 further reinforced the view that retinal imaging data often require stronger protection than simple pseudonymization workflows can provide. These overlapping rules raise compliance costs and slow model transfer across regions, which gives larger vendors a clearer advantage in the AI-driven retinal screening device market.

Other drivers and restraints analyzed in the detailed report include:

1. Shift Toward Point-of-Care and Primary Care Screening
2. Cloud Integration and Teleophthalmology Workflow Adoption
3. Reimbursement Fragmentation Across Care Settings

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Software held 55.16% of the AI-driven retinal screening device market share in 2025, while services are forecast to grow at 21.98% CAGR through 2031. That pattern shows where commercial value is concentrating, since recurring algorithm access, workflow integration, cloud hosting, and support contracts carry more durable revenue than device shipments alone. The AI-driven retinal screening device market is therefore moving toward platform economics where software becomes the main value layer, and hardware becomes the access point for image capture. Hardware still matters because image quality remains the base input for any screening system, but its pricing power is under pressure as more vendors seek compatibility across multi-brand camera fleets.

This balance also explains why workflow depth now matters more than stand-alone diagnostic performance. Vendors that can connect retinal screening outputs into EMR, referral, and teleophthalmology systems are in a stronger position to hold renewals and expand accounts over time. The AI-driven retinal screening device industry is, therefore, rewarding platforms that can manage operational tasks around the algorithm, not just the algorithm itself. Services should continue to rise because hospitals and health systems increasingly require onboarding, validation support, training, and post-market monitoring as part of procurement. That trend favors vendors that can package clinical, technical, and regulatory support together under longer-term contracts.

Fundus image-based AI held 56.18% share in 2025, while multi-modal AI is forecast to grow at 24.15% CAGR through 2031. Fundus-based systems led early adoption because they aligned with lower-cost non-mydriatic cameras, simpler primary care workflows, and the first wave of autonomous regulatory clearances. The AI-driven retinal screening device market has therefore built its initial scale on technologies that can be deployed without the cost and workflow demands of OCT-heavy pathways. Multi-modal AI is now expanding faster because providers want broader single-encounter screening that can assess diabetic retinopathy, age-related macular degeneration, and glaucoma from paired inputs.

Peer-reviewed research from 2025 showed that models combining fundus photography and OCT improved performance across multiple retinal conditions when compared with single-modality systems. Another 2025 study reported 93.52% sensitivity and 95.00% specificity for a hybrid glaucoma screening model based on fundus images, which supports continued progress toward broader clinical use. OCT-based AI, machine learning, deep learning, and natural language processing still serve narrower workflow roles, but their relevance rises as the AI-driven retinal screening device market moves from single-disease screening to more integrated retinal assessment. The AI-driven retinal screening device industry is likely to see more value shift toward technology stacks that support multi-disease decision support rather than narrow single-indication tools.

Complete Report Scope:

• By Component
  • Hardware
  • Software
  • Services
• By Technology
  • Fundus Image-Based AI
  • Optical Coherence Tomography-Based AI
  • Multi-Modal AI
  • Others (OCTA-Based AI, Ultra-Widefield (UWF) Imaging AI, etc.)
• By Deployment
  • Cloud-Based
  • On-Premise
• By Application
  • Diabetic Retinopathy
  • Age-Related Macular Degeneration
  • Glaucoma
  • Cataract
  • (Diabetic Macular Edema, Retinal Vein Occlusion, etc.)
• By End User
  • Hospitals
  • Ophthalmology Clinics
  • Diagnostic Centers
  • Academic and Research Institutions
  • Others (Telemedicine Providers, Mobile Clinics, etc.)
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 43.18% of the AI-driven retinal screening device market share in 2025, which kept it as the leading regional revenue base. The region benefits from the presence of multiple commercially available autonomous AI screening systems, a more established reimbursement pathway for autonomous retinal screening, and stronger provider familiarity with primary care-based diabetic eye screening workflows. The United States remained the center of regional demand because the rollout is extending beyond large academic centers into community and federally qualified health settings. A Utah deployment reported in November 2025 found that around 1 in 4 screened diabetes patients required urgent ophthalmology referral within 3 months, which supports the practical screening value of scaled primary care use. Europe ranked as the second-largest regional market, with 13 CE-certified AI diabetic retinopathy systems in commercial deployment as of 2026.

Germany, the United Kingdom, and France have remained the leading European adoption centers. The United Kingdom also contributed early teleophthalmology evidence through the HERMES trial, which helped support broader confidence in remote retinal triage. Europe still faces a slower operating environment than North America because cross-border data governance and retraining requirements are becoming more demanding under newer regulatory rules. That means Europe remains important in the AI-driven retinal screening device market, but growth can be more dependent on regulatory navigation and local deployment design.

Asia-Pacific is forecast to grow at 25.67% CAGR through 2031, which makes it the fastest-growing region in the AI-driven retinal screening device market. The region combines very large diabetes populations, specialist shortages, and active healthcare digitization programs. China remains central because regulators are formalizing dataset expectations for diabetic retinopathy AI, while providers are using AI to scale screening beyond specialist-heavy hospital models. India is also important because it combines a very high diabetes burden with a visible local vendor base and persistent ophthalmologist shortages.

1. AEYE Health
2. Airdoc Technology (Beijing) Co., Ltd.
3. Bosch Healthcare Solutions GmbH
4. Canon
5. Carl Zeiss
6. Digital Diagnostics
7. Eyenuk, Inc.
8. EyRIS Pte. Ltd.
9. Heidelberg Engineering
10. Intelligent Retinal Imaging Systems, Inc.
11. Kowa Company, Ltd.
12. Nidek
13. Optomed Plc
14. Remidio Innovative Solutions Pvt. Ltd.
15. RetinaLyze System A/S
16. Shenzhen Sibionics Technology Co., Ltd.
17. Thirona B.V.
18. Topcon
19. Verily Life Sciences LLC
20. Visionix Ltd.
21. VUNO Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Diabetes Burden and Undiagnosed Retinopathy Risk
  • 4.2.2 Shortage of Ophthalmologists and Specialist Bottlenecks
  • 4.2.3 Shift Toward Point-of-Care and Primary Care Screening
  • 4.2.4 Cloud Integration and Teleophthalmology Workflow Adoption
  • 4.2.5 Regulatory Clearance Momentum for Autonomous Screening
  • 4.2.6 Under-Served Rural and Non-Acute Screening Channels
• 4.3 Market Restraints
  • 4.3.1 Data Privacy, Model Governance, and Cross-Border Data Restrictions
  • 4.3.2 Reimbursement Fragmentation Across Care Settings
  • 4.3.3 Clinical Validation Burden Across Multiple Pathologies
  • 4.3.4 High Integration Friction with Legacy Imaging and EHR Systems
• 4.4 Value Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)

• 5.1 By Component
  • 5.1.1 Hardware
  • 5.1.2 Software
  • 5.1.3 Services
• 5.2 By Technology
  • 5.2.1 Fundus Image-Based AI
  • 5.2.2 Optical Coherence Tomography-Based AI
  • 5.2.3 Multi-Modal AI
  • 5.2.4 Others (OCTA-Based AI, Ultra-Widefield (UWF) Imaging AI, etc.)
• 5.3 By Deployment
  • 5.3.1 Cloud-Based
  • 5.3.2 On-Premise
• 5.4 By Application
  • 5.4.1 Diabetic Retinopathy
  • 5.4.2 Age-Related Macular Degeneration
  • 5.4.3 Glaucoma
  • 5.4.4 Cataract
  • 5.4.5 (Diabetic Macular Edema, Retinal Vein Occlusion, etc.)
• 5.5 By End User
  • 5.5.1 Hospitals
  • 5.5.2 Ophthalmology Clinics
  • 5.5.3 Diagnostic Centers
  • 5.5.4 Academic and Research Institutions
  • 5.5.5 Others (Telemedicine Providers, Mobile Clinics, etc.)
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 India
    • 5.6.3.3 Japan
    • 5.6.3.4 South Korea
    • 5.6.3.5 Australia
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East and Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East and Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.3.1 AEYE Health
  • 6.3.2 Airdoc Technology (Beijing) Co., Ltd.
  • 6.3.3 Bosch Healthcare Solutions GmbH
  • 6.3.4 Canon Inc.
  • 6.3.5 Carl Zeiss Meditec AG
  • 6.3.6 Digital Diagnostics Inc.
  • 6.3.7 Eyenuk, Inc.
  • 6.3.8 EyRIS Pte. Ltd.
  • 6.3.9 Heidelberg Engineering GmbH
  • 6.3.10 Intelligent Retinal Imaging Systems, Inc.
  • 6.3.11 Kowa Company, Ltd.
  • 6.3.12 NIDEK Co., Ltd.
  • 6.3.13 Optomed Plc
  • 6.3.14 Remidio Innovative Solutions Pvt. Ltd.
  • 6.3.15 RetinaLyze System A/S
  • 6.3.16 Shenzhen Sibionics Technology Co., Ltd.
  • 6.3.17 Thirona B.V.
  • 6.3.18 Topcon Corporation
  • 6.3.19 Verily Life Sciences LLC
  • 6.3.20 Visionix Ltd.
  • 6.3.21 VUNO Inc.

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

• 7.1 White-Space and Unmet-Need Assessment